<DOC>
	<DOC>NCT01318902</DOC>
	<brief_summary>This study will include patients with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of IXAZOMIB administered orally.</brief_summary>
	<brief_title>Study of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male or female patients 18 years or older Biopsyproven systemic relapsed or refractory lightchain (AL) amyloidosis, which after at least 1 prior therapy, in the investigator's opinion, requires further treatment If received stem cell transplant, must be at least 3 months posttransplantation and recovered from side effects Must have measurable disease defined as serum differential free light chain concentration ≥ 40mg/L Must have objective measurable organ (heart or kidney) amyloid involvement Must have cardiac biomarker risk stage I or II disease Must have adequate hematologic, hepatic, and renal function Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse Voluntary written consent Exclusion Criteria Peripheral neuropathy that is greater or equal to Grade 2 Cardiac status as described in protocol Severe diarrhea (≥ Grade 3) not controllable with medication or requires administration of total parenteral nutrition Known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of MLN9708 Uncontrolled infection requiring systematic antibiotics Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigenpositive status, or known or suspected active hepatitis C infection Presence of other active malignancy with the exception of nonmelanoma skin cancer, cervical cancer, treated earlystage prostate cancer provided that prostatespecific antigen is within normal limit, or any completely resected carcinoma in situ Female patients who are lactating or pregnant Major surgery within 14 days before the first dose of study drug Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>